|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eprosartan#Adverse Reactions]] |
| {{Eprosartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| TEVETEN® has been evaluated for safety in more than 3,300 healthy volunteers and patients worldwide, including more than 1,460 patients treated for more than 6 months, and more than 980 patients treated for 1 year or longer. TEVETEN® was well tolerated at doses up to 1200 mg daily. Most adverse events were of mild or moderate severity and did not require discontinuation of therapy. The overall incidence of adverse experiences and the incidences of specific adverse events reported with eprosartan were similar to placebo.
| |
| | |
| Adverse experiences were similar in patients regardless of age, gender, or race. Adverse experiences were not dose-related.
| |
| | |
| In placebo-controlled clinical trials, about 4% of 1,202 patients treated with TEVETEN® discontinued therapy due to clinical adverse experiences, compared to 6.5% of 352 patients given placebo.
| |
| | |
| Adverse Events Occurring at an Incidence of 1% or More Among Eprosartan-treated Patients
| |
| | |
| The following table lists adverse events that occurred at an incidence of 1% or more among eprosartan-treated patients who participated in placebo-controlled trials of 8 to 13 weeks' duration, using doses of 25 mg to 400 mg twice daily, and 400 mg to 1200 mg once daily. The overall incidence of adverse events reported with TEVETEN®(54.4%) was similar to placebo (52.8%).
| |
| | |
| {|
| |
| |[[File:TEVETEN02.jpg|thumb|800px]]
| |
| |}
| |
| | |
| The following adverse events were also reported at a rate of 1% or greater in patients treated with eprosartan, but were as, or more, frequent in the placebo group: headache, myalgia, dizziness, sinusitis, diarrhea, bronchitis, dependent edema, dyspepsia, and chest pain.
| |
| | |
| Facial edema was reported in 5 patients receiving eprosartan. Angioedema has been reported with other angiotensin II antagonists.
| |
| | |
| Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.
| |
| | |
| In addition to the adverse events above, potentially important events that occurred in at least two patients/subjects exposed to eprosartan or other adverse events that occurred in <1% of patients in clinical studies are listed below. It cannot be determined whether events were causally related to eprosartan:
| |
| | |
| '''Body as a Whole''': alcohol intolerance, [[asthenia]], substernal chest pain, [[peripheral edema]], [[fatigue]], fever, [[hot flushes]], [[influenza-like symptoms]], [[malaise]], [[rigors]], pain;
| |
| | |
| '''Cardiovascular''': [[angina pectoris]], [[bradycardia]], abnormal ECG, specific abnormal ECG, [[extrasystoles]], [[atrial fibrillation]], [[hypotension]] (including [[orthostatic hypotension]]), [[tachycardia]], [[palpitations]];
| |
| | |
| '''Gastrointestinal''': [[anorexia]], [[constipation]], dry mouth, [[esophagitis]], [[flatulence]], [[gastritis]], [[gastroenteritis]], [[gingivitis]], [[nausea]], [[periodontitis]], toothache, [[vomiting]];
| |
| | |
| '''Hematologic''': [[anemia]], [[purpura]];
| |
| | |
| '''Liver and Biliary''': increased SGOT, increased SGPT;
| |
| | |
| '''Metabolic and Nutritional''': increased creatine phosphokinase, [[diabetes mellitus]], [[glycosuria]], [[gout]], [[hypercholesterolemia]], [[hyperglycemia]], [[hyperkalemia]], [[hypokalemia]], [[hyponatremia]];
| |
| | |
| '''Musculoskeletal''': [[arthritis]], aggravated [[arthritis]], [[arthrosis]], skeletal pain, [[tendinitis]], back pain;
| |
| | |
| '''Nervous System/Psychiatric''': [[anxiety]], [[ataxia]], [[insomnia]], [[migraine]], [[neuritis]], [[nervousness]], [[paresthesia]], [[somnolence]], [[tremor]], [[vertigo]];
| |
| | |
| '''Resistance Mechanism''': [[herpes simplex]], [[otitis externa]], [[otitis media]], [[upper respiratory tract infection]];
| |
| | |
| '''Respiratory''': [[asthma]], [[epistaxis]];
| |
| | |
| '''Skin and Appendages''': [[eczema]], [[furunculosis]], [[pruritus]], [[rash]], [[maculopapular rash]], increased sweating;
| |
| | |
| '''Special Senses''': [[conjunctivitis]], abnormal vision, [[xerophthalmia]], [[tinnitus]];
| |
| | |
| '''Urinary''': [[albuminuria]], [[cystitis]], [[hematuria]], micturition frequency, [[polyuria]], renal calculus, urinary incontinence;
| |
| | |
| '''Vascular''': leg cramps, peripheral [[ischemia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TEVETEN (EPROSARTAN MESYLATE) TABLET [ABBOTT LABORATORIES] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7cde57a7-eded-4c22-b1c7-98afc5546997 | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Imidazoles]]
| |
| [[Category:Thiophenes]]
| |
| [[Category:Benzoic acids]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |